We are pleased to announce the launch of CARE1 Project, which officially started on May 1^st, 2023.

The project was submitted under the Call HORIZON-MISS-2022-CANCER-01-03, focused on pragmatic clinical trials to optimize treatments for patients with refractory cancers. CARE1 project is led by Gustave Roussy, with Prof. Laurence Albiges serving as the principal investigator.

The European Commission has signed the Grant Agreement and approved the project on April 21^st, with Grant N° 101104801. Over the next 60 months, CARE1 will be conducting a prospective randomized Phase III study, in a first-line setting for patients with metastatic clear cell RCC, comparing ICI-ICI vs ICI-VEGFR TKI approaches stratified on PD-L1 by local determination. The trial will enroll 1,200 patients and gathers eight European countries including France, Spain, Germany, Netherlands, Italy, Czech Republic, Austria, and the UK. Four members of Care 1 partners are members of the Cancer Core Europe CCE: Gustave Roussy, VHIO, INT, and NKI. The project’s budget is approximately 5.5 million EUR.

CARE1 presents a unique opportunity to build a large-scale platform to define new biomarker-based therapy guidelines, as well as to investigate quality of life, patient-reported outcomes, and Health-Economic in a frontline setting. We are excited about the potential of this project to accelerate progress in the fight against cancer, and we will keep you updated on our progress in the coming months.